Y-mAbs Therapeutics, Inc. License Agreements
5 Contracts & Agreements
- License Agreement, entered into on October 29, 2024 and effective October 23, 2024, by and between Y-mAbs Therapeutics, Inc. and Nobelpharma Co., Ltd (Filed With SEC on November 4, 2024)
- Amendment No. 2, dated March 18, 2021 to License Agreement, dated as of August 20, 2015 between Registrant and Memorial Sloan Kettering Cancer Center (Filed With SEC on May 9, 2022)
- Amendment No. 1, dated March 18, 2021 to License Agreement, dated as of August 20, 2015 between Registrant and Memorial Sloan Kettering Cancer Center (Filed With SEC on May 6, 2021)
- License Agreement dated December 17, 2020 between Y-mabs Therapeutics, Inc., and SciClone Pharmaceuticals International Ltd (Filed With SEC on December 22, 2020)
- License Agreement, effective as of April 15, 2020, by and among the Company, Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology (Filed With SEC on April 21, 2020)
